Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group

Beatriz Rey-Búa; Carlos Grande; José Javier Sánchez Blanco; Pau Abrisqueta; Antonio Gutiérrez; Ángel Ramírez Páyer; Eva Giné; Izaskun Zeberio; María José Terol; Fátima de la Cruz Vicente; Rafael Andreu; M.J. Ramírez; Adolfo de la Fuente; María C. Viguria; María Jesús Peñarrubia; Ana Jiménez Ubieto; Santiago Montes‐Moreno; Armando López‐Guillermo; M. D. Caballero; Alejandro Martı́n

doi:10.1158/1078-0432.ccr-24-0183

Abstract

This phase II clinical trial evaluated the combination of ibrutinib with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in patients with nongerminal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rey-Búa et al. (2024) studied this question.

synapsesocial.com/papers/68e63f56b6db6435875d08d9 https://doi.org/10.1158/1078-0432.ccr-24-0183

View at Publisher

Ask AI

Bookmark

Share

Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group

Abstract

Discussion

Cite This Study

Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Clinical Cancer Research

Keep reading

More related papers

More from Clinical Cancer Research